Literature DB >> 19212815

NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy.

Han-Ming Shen1, Vinay Tergaonkar.   

Abstract

It has become increasingly clear that deregulation of the NFkappaB signaling cascade is a common underlying feature of many human ailments including cancers. The past two decades of intensive research on NFkappaB has identified the basic mechanisms that govern the functioning of this pathway but uncovering the details of why this pathway works differently in different cellular contexts or how it interacts with other signaling pathways remains a challenge. A thorough understanding of these processes is needed to design better and more efficient therapeutic approaches to treat complex diseases like cancer. In this review, we summarize the literature documenting the involvement of NFkappaB in cancer, and then focus on the approaches that are being undertaken to develop NFkappaB inhibitors towards treatment of human cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212815     DOI: 10.1007/s10495-009-0315-0

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  96 in total

1.  Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Authors:  Alexander V Gasparian; Catherine A Burkhart; Andrei A Purmal; Leonid Brodsky; Mahadeb Pal; Madhi Saranadasa; Dmitry A Bosykh; Mairead Commane; Olga A Guryanova; Srabani Pal; Alfiya Safina; Sergey Sviridov; Igor E Koman; Jean Veith; Anton A Komar; Andrei V Gudkov; Katerina V Gurova
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

Review 2.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

3.  Anticancer cardamonin analogs suppress the activation of NF-kappaB pathway in lung cancer cells.

Authors:  Weiyan He; Yu Jiang; Xuebing Zhang; Yue Zhang; Honglei Ji; Nan Zhang
Journal:  Mol Cell Biochem       Date:  2014-01-04       Impact factor: 3.396

4.  Ablation of miR-146b in mice causes hematopoietic malignancy.

Authors:  Takahiro Mitsumura; Yoshiaki Ito; Tomoki Chiba; Takahide Matsushima; Ryota Kurimoto; Yoko Tanaka; Tomomi Kato; Keisuke Uchida; Takashi Ito; Kouhei Yamamoto; Yoshinobu Eishi; Masanobu Kitagawa; Yasunari Miyazaki; Naohiko Inase; Hiroshi Asahara
Journal:  Blood Adv       Date:  2018-12-11

5.  Modulatory effect of phytoglycoprotein (38 kDa) on cyclin D1/CDK4 in BNL CL.2 cells induced by N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  Jin Lee; Kye-Taek Lim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-20       Impact factor: 3.000

6.  Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection.

Authors:  Zhiliang Wu; Thidarut Boonmars; Sirintip Boonjaraspinyo; Isao Nagano; Somchai Pinlaor; Anucha Puapairoj; Puangrat Yongvanit; Yuzo Takahashi
Journal:  Parasitol Res       Date:  2011-03-05       Impact factor: 2.289

7.  Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB.

Authors:  Lida Zhang; Yangqiu Bai; Yuxiu Yang
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

Review 8.  The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.

Authors:  Yong Lin; Lang Bai; Wenjie Chen; Shanling Xu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

Review 9.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways.

Authors:  Aaron J Schetter; Niels H H Heegaard; Curtis C Harris
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

10.  Gene expression profiling in sinonasal adenocarcinoma.

Authors:  Dominique Tripodi; Sylvia Quéméner; Karine Renaudin; Christophe Ferron; Olivier Malard; Isabelle Guisle-Marsollier; Véronique Sébille-Rivain; Christian Verger; Christian Géraut; Catherine Gratas-Rabbia-Ré
Journal:  BMC Med Genomics       Date:  2009-11-10       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.